keine Finanzberatung

TMO · Thermo Fisher Scientific

Lab instruments and services for pharma research

Risiko 4/10 · LOW-MODERATE RISK · lab-tools giant · $613.78 ▼ 0.75%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $613.78
  • Market cap $226.9B
  • P/E (ttm) 33
  • Div yield 0.31%
  • 52-wk range $435.27 – $647.00
  • Index rank #64 / —

Wichtigste Risiken

  • Pharma R&D budget cuts (Shareholders) — MED
  • US academic and NIH funding squeeze (Shareholders) — MED
  • China demand and tariff exposure (Shareholders) — MED
  • Overpaying for acquisitions (Shareholders) — LOW

Fazit

A quality picks-and-shovels franchise in a funding downcycle — patient money gets paid, but the recovery timeline isn't Thermo's to decide.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.